Medigen Biotechnology Corporation

Medigen Biotechnology Corporation

TTPEX:3176
30.00
TWD
-0.15
(-0.50%)
-2.61EPS
4.68BMarket Cap
Medigen Biotechnology Corporation
TPEX:3176
(Taipei Exchange)

Recent

price

30.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
TWD
0.81
1.15
0.92
0.56
2.68
2.62
2.88
3.08
2.94
3.98
4.43
28.22
7.59
8.31
9.85
11.36
9.17
Revenue per Share
-1.24
-1.95
2.09
-2.79
-5.06
-3.9
-4.1
-3.37
-3.19
-1.84
-2.43
-0.38
-4.86
-4.03
-1.47
-0.78
-1.82
Basic EPS, GAAP
-3.15
-1
-11.36
-8.07
-7.72
-1.59
-7.97
-3.65
-4.51
-4.83
-5.96
2.69
-9.27
-3.91
-0.15
-0.24
-3.5
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.22
0.27
0.39
0.41
- -
Dividend per Share
7.69
7.67
15.02
20.74
20.81
17.98
15.87
13.25
11.08
9.79
13.06
17.18
15.73
11.42
11.36
11.12
10.6
Book Value per Share
6.5
6.34
13.58
19.48
18.15
15.55
13.43
11.1
9.5
8.49
11.94
16.29
14.92
10.66
10.64
10.45
9.95
Tangible Book Value per Share
87
99
121
131
139
139
139
139
139
139
139
139
139
139
139
139
138
Basic Weighted Avg Shares
71
114
111
73
372
363
400
427
407
552
616
3,922
1,056
1,158
1,373
1,583
1,269
Sales/Revenue/Turnover
-177.35
-230.39
-349.04
-809.69
-198.4
-207.13
-187.63
-151.25
-187.22
-130.77
-148.48
19.57
-155.86
-105.26
-15.35
-6.64
-19.27
Operating Margin (%)
24
26
40
38
83
127
159
217
212
213
219
198
192
178
175
176
181
Depreciation Expense
-108
-192
253
-364
-702
-541
-568
-467
-443
-256
-338
-53
-676
-561
-205
-109
-252
Net Income, GAAP
- -
- -
13.89
- -
- -
- -
- -
- -
- -
- -
- -
5.78
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-152.7
-168.85
227.2
-499.3
-188.79
-149.01
-142.12
-109.19
-108.68
-46.3
-54.9
-1.34
-64.01
-48.48
-14.91
-6.88
-19.89
Profit Margin (%)
440
483
1,464
1,973
1,397
1,173
806
822
892
382
2,088
3,853
5,681
2,928
2,736
2,742
3,167
Working Capital
- -
- -
41
- -
191
652
695
863
955
1,179
682
667
2,404
717
719
695
1,482
LT Debt
808
912
2,007
3,067
3,659
3,464
3,538
3,180
2,941
2,685
4,499
6,426
6,471
4,997
5,038
4,716
4,710
Total Equity
- -
- -
-21.06
- -
- -
- -
- -
- -
- -
- -
- -
11.28
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
17.65
- -
- -
- -
- -
- -
- -
- -
- -
-17.56
- -
- -
- -
- -
- -
Return on Capital (%)
-16.07
-23.22
17.89
-15.25
-24.54
-20.11
-24.21
-23.11
-26.23
-17.65
-21.28
-2.5
-29.46
-29.65
-12.9
-6.95
-15.93
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
258
257
234
LT Borrowings
421
1,117
1,102
LT Finance Leases
274
371
381
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
139
139
139
Market Capitalization
4,514
4,402
4,681

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
3,487
3,878
3,850
Cash, Cash Equivalents & STI
2,527
2,871
2,744
Accounts Receivable, Net
197
175
196
Inventories
581
652
714
Total Current Liabilities
745
716
683
Payables & Accruals
- -
- -
- -
ST Debt
258
257
234
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.85%
3.03%
-6.39%
Free Cash Flow
-28.48%
-137.16%
58.41%
Net Income, GAAP
94.48%
194.57%
-46.84%
Sales/Revenue/Turnover
56.7%
101.52%
15.28%
Total Cash Common Dividend
- -
- -
6.65%

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
251
354
437
331
1,373
2025
499
361
396
327
1,583
2026
261
285
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.54
0.08
-0.19
-0.82
-1.47
2025
0.74
-0.27
-0.41
-0.84
-0.78
2026
-0.38
-0.19
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.39
2025
- -
- -
- -
- -
0.41
2026
- -
- -
- -
- -
- -
Business
Medigen Biotechnology Corp. (3176.TWO) is a Taiwan-based biopharmaceutical company that develops, manufactures and commercializes vaccines and biotherapeutics. The company offers a portfolio of recombinant protein vaccines, including its flagship Medigen COVID-19 vaccine (MVC-COV1901), influenza vaccines, and candidates for dengue fever, hand-foot-mouth disease, and third-generation COVID-19 boosters; it also provides contract development and manufacturing organization (CDMO) services for biologics, monoclonal antibodies, and cell therapies, along with diagnostic kits and related research tools. Medigen operates primarily in the biotechnology and vaccine segment, targeting government health agencies, hospitals, and pharmaceutical partners in Asia, with expanding efforts into global markets including Europe and the Americas. Founded in 1999 and headquartered in Taipei, Taiwan, the company maintains research and production facilities in Taiwan and focuses on innovative vaccine platforms such as protein subunit and adenovirus vector technologies. Its subsidiaries include Medigen Vaccine Biologics Corp., which handles large-scale manufacturing, and it collaborates with international partners like the International Vaccine Institute and Dynavax Technologies for technology transfer and clinical development. Medigen serves public health sectors and commercial biotech firms, with products distributed across Taiwan, Indonesia, Thailand, and other regions through strategic supply agreements. In the last two years, Medigen has advanced several key initiatives, including the commercialization of its MVC-COV1901 vaccine with regulatory approvals in Taiwan and export deals to multiple Southeast Asian countries; it secured a major partnership with the Taiwan government for domestic vaccine stockpiling and launched Phase III trials for its dengue fever vaccine candidate. The company completed a significant funding round in 2024 via equity issuance to support CDMO expansion and announced a strategic alliance with a European biotech firm for next-generation mRNA vaccine co-development in late 2025. Additionally, Medigen reorganized its operations to enhance GMP-compliant facilities for international tenders, positioning it for growth in the post-pandemic biopharma market.